Standard BioTools Inc. (FRA:FLB)

Germany flag Germany · Delayed Price · Currency is EUR
1.290
+0.020 (1.57%)
At close: Dec 1, 2025
-24.12%
Market Cap497.47M
Revenue (ttm)144.67M
Net Income (ttm)-109.31M
Shares Outn/a
EPS (ttm)-0.29
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,719
Average Volume911
Open1.250
Previous Close1.270
Day's Range1.250 - 1.290
52-Week Range0.805 - 2.060
Betan/a
RSI69.47
Earnings DateFeb 6, 2026

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provide... [Read more]

Industry Laboratory Analytical Instruments
Founded 1999
Employees 818
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol FLB
Full Company Profile

Financial Performance

In 2024, Standard BioTools's revenue was $174.43 million, an increase of 64.03% compared to the previous year's $106.34 million. Losses were -$184.90 million, 147.7% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.